<DOC>
	<DOCNO>NCT01719003</DOCNO>
	<brief_summary>This study investigate efficacy safety two dos ( high low ) empagliflozin combination metformin ( 500 mg 1000 mg ) administer twice daily patient type 2 diabetes mellitus ( T2DM ) . Study compare four dose combination empagliflozin + metformin versus individual component 24 week treatment .</brief_summary>
	<brief_title>Safety Efficacy Study Empagliflozin Metformin 24 Weeks Treatment Naive Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis type 2 diabetes mellitus prior inform consent 2 . Male female patient diet exercise regimen drugnaive , define absence oral antidiabetic therapy 12 week prior randomization 3 . HbA1c &gt; =7.5 % &lt; = 12 % ( &gt; =58.5 mmol/mol &lt; =107.7 mmol/mol ) 4 . Body Mass Index ( BMI ) &lt; = 45 kg/m2 screen Exclusion criterion : 1 . Uncontrolled hyperglycemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast placebo runin confirm second laboratory measurement ( day ) 2 . Any antidiabetic drug within 12 week prior randomization 3 . Impaired renal function , define estimate creatinine clearance rate ( eCCr ) &lt; 60 ml/min ( CockcroftGault formula ) determine screen and/or runin period 4 . Contraindications metformin accord local label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>